Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07208591 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 2, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 3 to 15
    • Eligibility criteria expanded, about 32 words
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2025 to Oct 31, 2025
    • Site details revised at 3 of 3 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy, safety and tolerability of STSA-1002 injection in patients with acute respiratory distress syndrome
Trial Details
NCT Number NCT07208591
Lead Sponsor Staidson (Beijing) Biopharmaceuticals Co., Ltd
Conditions
(from sponsor)		 Acute Respiratory Distress Syndrome (ARDS)
Related terms Respiratory Distress Syndrome
Enrollment 406 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov